Haima Therapeutics, LLC
SynthoPlate (SP), a platelet-inspired synthetic hemostatic nanoparticle to reverse antiplatelet therapy complications and restore hemostasis
- Sector
- Medtech
- Total capital
- $5.9M
- Federal grants
- $5.9M
- 11 awards · 2018–2025
- Rank in peer group#16 of 41
- Private capital raised
- None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 0
- 4 pending
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase II · A Novel Platelet-Inspired Nanotechnology to Restore Hemostasis in Patients on Antiplatelet Agents$945K
- Federal grantHealth and Human S · Phase II · SynthoPlate: Intravenous Hemostatic Nanotechnology to Mitigate Bleeding in Thrombocytopenia$50K
- Federal grantHealth and Human S · Phase II · SynthoPlate: Intravenous Hemostatic Nanotechnology to Mitigate Bleeding in Thrombocytopenia$113K
- Federal grantHealth and Human S · Phase II · SynthoPlate: Intravenous Hemostatic Nanotechnology to Mitigate Bleeding in Thrombocytopenia$972K
- Federal grantHealth and Human S · Phase II · SynthoPlate: Intravenous Hemostatic Nanotechnology to Mitigate Bleeding in Thrombocytopenia$994K
- Federal grantHealth and Human S · Phase II · SynthoPlate: Intravenous Hemostatic Nanotechnology to Mitigate Bleeding in Thrombocytopenia$994K
- Federal grantNSF · Phase II · SBIR Phase II: Manufacturing and Characterization of a Synthetic Platelet (SynthoPlateTM) Technology$949K
Show 4 earlier federal awards
- Federal grantHealth and Human S · Phase I · SynthoPlate: Intravenous Hemostatic Nanotechnology to Mitigate Bleeding in Thrombocytopenia$300K
- Federal grantHealth and Human S · Phase I · SynthoPlate: Intravenous Hemostatic Nanotechnology to Mitigate Bleeding in Thrombocytopenia$300K
- Federal grantDefense · Phase I · Logistical and Functional Evaluation of SynthoPlateTM (Intravenous Synthetic Platelet) Technology for Pre-Hospital Hemorrhage Control$100K
- Federal grantNSF · Phase I · SBIR Phase I: Manufacturing and Characterization of a Synthetic Platelet (SynthoPlateTM) Technology$225K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 41 peers
Line = medianMedtech · Molecule
- Federal grants#16 · top 39%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
No founders are linked to this company yet.
Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.
Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026
Claim this profile to add your teamWhat it has protected
USPTO · 0 granted of 4- PendingPlatelet-binding Proteins And Conjugates Thereof, Particles Comprising Them And Uses ThereofUSPTOApplication 19130803
- PendingLyophilization Buffers For Peptide-decorated LiposomesUSPTOApplication 19130805
- PendingLyophilization Buffers For Peptide-decorated LiposomesUSPTOApplication PCTUS2023080229
Show all 4 patent records
- Platelet-binding Proteins And Conjugates Thereof, Particles Comprising Them And Uses ThereofJul 9, 2026 · Application 19130803Pending
- Lyophilization Buffers For Peptide-decorated LiposomesApplication 19130805Pending
- Lyophilization Buffers For Peptide-decorated LiposomesApplication PCTUS2023080229Pending
- Platelet-binding Proteins And Conjugates Thereof, Particles Comprising Them And Uses ThereofApplication PCTUS2023080225Pending
Related companies, and why
- Haima Therapeutics LLCShares a founder: MICHAEL BRUCKMAN
- OMNISPEECH, LLCSimilar federal contract value in Medtech · null in contracts
- ION CHANNEL PHARMACOLOGY LLCSimilar federal contract value in Medtech · null in contracts
- Radiant Images Inc.Similar federal contract value in Medtech · null in contracts
- ANABIOS CORPORATIONSimilar federal contract value in Medtech · null in contracts
- INVIBRAGEN INC.Similar federal contract value in Medtech · null in contracts
Regulatory activity · Medtech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .